Page last updated: 2024-09-02

ci 988 and naltrexone

ci 988 has been researched along with naltrexone in 2 studies

Compound Research Comparison

Studies
(ci 988)
Trials
(ci 988)
Recent Studies (post-2010)
(ci 988)
Studies
(naltrexone)
Trials
(naltrexone)
Recent Studies (post-2010) (naltrexone)
1478148,7451,2282,642

Protein Interaction Comparison

ProteinTaxonomyci 988 (IC50)naltrexone (IC50)
Cytochrome P450 2D6Homo sapiens (human)1
Delta-type opioid receptorMus musculus (house mouse)0.0051
Delta-type opioid receptorRattus norvegicus (Norway rat)0.0063
Kappa-type opioid receptorMus musculus (house mouse)0.006
Mu-type opioid receptorRattus norvegicus (Norway rat)0.0005
Kappa-type opioid receptorRattus norvegicus (Norway rat)0.0005
Mu-type opioid receptorHomo sapiens (human)0.006
Delta-type opioid receptorHomo sapiens (human)0.0319
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)0.0093
Kappa-type opioid receptorHomo sapiens (human)0.0377
Mu-type opioid receptorMus musculus (house mouse)0.0076
Mu-type opioid receptorCavia porcellus (domestic guinea pig)0.0004

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Blommaert, A; Fournié-Zaluski, MC; Noble, F; Roques, BP1
Boucher, M; Coudoré-Civiale, MA; Eschalier, A; Fournié-Zaluski, MC; Méen, M; Roques, BP1

Other Studies

2 other study(ies) available for ci 988 and naltrexone

ArticleYear
A selective CCKB receptor antagonist potentiates, mu-, but not delta-opioid receptor-mediated antinociception in the formalin test.
    European journal of pharmacology, 1995, Jan-24, Volume: 273, Issue:1-2

    Topics: Analgesics; Animals; Disulfides; Enkephalins; Formaldehyde; Indoles; Male; Meglumine; Mice; Morphine; Naloxone; Naltrexone; Pain Measurement; Phenylalanine; Receptors, Cholecystokinin; Receptors, Opioid, delta; Receptors, Opioid, mu

1995
Enhancement of the effects of a complete inhibitor of enkephalin-catabolizing enzymes, RB 101, by a cholecystokinin-B receptor antagonist in diabetic rats.
    British journal of pharmacology, 2001, Volume: 133, Issue:1

    Topics: Aminopeptidases; Animals; Diabetes Mellitus, Experimental; Disulfides; Drug Synergism; Indoles; Male; Meglumine; Naloxone; Naltrexone; Neprilysin; Pain; Pain Measurement; Phenylalanine; Pressure; Rats; Rats, Sprague-Dawley; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Time Factors; Vocalization, Animal; Weight Loss

2001